RESEARCH · RETATRUTIDE · EATING BEHAVIOUR
Retatrutide and Eating Behaviour: Appetite, Hunger, Exit Interviews and New Patient-Reported Outcome Tools
PurixLab’s Retatrutide 10mg is a research vial of retatrutide (LY3437943), a single peptide that activates the GIP, GLP-1 and glucagon receptors. Our earlier articles cover the glucagon receptor and energy expenditure, safety and tolerability and the TRIUMPH sleep apnoea and knee osteoarthritis data. This article looks at the intake side of the equation: what trial participants reported about appetite, hunger and eating behaviour, how researchers are building new questionnaires to measure those changes, and what animal studies add. These are findings from published research; the vial is supplied for laboratory research use only, and nothing here is treatment guidance or a claim about any PurixLab product.
Two routes to weight loss
The discovery paper framed retatrutide as working on both sides of energy balance. In obese mice, weight loss was augmented by glucagon receptor-mediated increases in energy expenditure on top of the reduction in calorie intake driven by the GIP and GLP-1 receptors [1]. A separate clinical pharmacology report is titled “The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying” [2]; it has no abstract in PubMed, so we do not summarise its data. Appetite and eating behaviour are therefore expected to matter, but in people they can only be measured by asking participants, which is where patient-reported outcome research comes in.
The phase 2 trials behind the data
Most of the patient-reported work comes from two phase 2 trials. The obesity trial enrolled 338 adults for 48 weeks; mean weight change at 48 weeks reached -24.2% in the 12 mg group versus -2.1% with placebo, and gastrointestinal events were the most common adverse events [3]. The type 2 diabetes trial randomised 281 participants to placebo, dulaglutide 1.5 mg or one of several retatrutide regimens, with HbA1c as the primary endpoint [4].
Appetite and eating behaviour in type 2 diabetes
A pre-specified exploratory analysis of the diabetes trial used two standard instruments in 275 adults: an Appetite Visual Analogue Scale (VAS) and the Eating Inventory, which scores perceived hunger, disinhibition (the tendency to overeat) and dietary restraint [5]. The main findings were:
- Compared with placebo, participants on retatrutide 4 mg or more reported greater reductions in overall appetite, hunger and prospective food consumption at week 24 [5].
- Perceived hunger and disinhibition improved more than with placebo in the 8 mg and 12 mg groups at weeks 24 and 36; dietary restraint increased versus placebo only in the 12 mg group at week 36 [5].
- Differences versus dulaglutide were less consistent [5].
- Reductions in perceived hunger and disinhibition and increases in restraint correlated with weight reduction at week 36, with r = 0.28, 0.36 and 0.31 [5].
Those correlations are modest: each explains only a small share of the variation in weight change. The analysis also cannot say whether eating less drives weight loss or whether people who lose weight for other reasons report their eating differently.
A companion analysis in the obesity trial is published as a letter titled “Association between patient-reported eating behaviours and weight change” [6]. It has no abstract in PubMed, so we do not report its figures.
What participants said in exit interviews
Forty participants leaving the phase 2 obesity trial in the US took part in semi-structured telephone interviews; 36 had received retatrutide and 4 placebo [7]. Thirty-one of the 36 treated participants described changes in eating within the first 8 weeks: eating less often or smaller portions, feeling hungry less often, feeling full after eating, different food preferences and a greater sense of control. Many described feeling self-confident (32) or happy (25), and improved mobility (27) or energy (24). The interviews also captured downsides: a few reported reduced social participation because of adverse events (2) or new eating habits (2), and 3 were frustrated by disappointing weight loss. Of the thirty treated participants who had weight reduction as a goal, 76.7% said they reached it [7].
Qualitative studies describe experiences rather than measure effects. With only 4 placebo participants, the interviews cannot show what part of these changes is specific to the drug.
Building better questionnaires
The same research team used those interviews to build two new instruments. The Eating Behavior and Appetite Questionnaire (EBAQ) was developed from a literature review, the 40 exit interviews and interviews with 3 obesity clinicians, then tested in cognitive interviews with 24 adults; the result is a 21-item questionnaire with three domains covering eight appetite and eating concepts [8]. The Weight and Emotions Scale (WES) followed the same path, with 20 cognitive interviews, and has 16 items covering 13 emotion-related concepts [9]. Both papers report content development only; measurement properties such as reliability and responsiveness to change still have to be established.
What animal studies add
- MC4R-deficient mice. In mice lacking the melanocortin 4 receptor, a key hypothalamic appetite pathway, 21 days of treatment reduced body weight by 24.1% with retatrutide, 19.7% with semaglutide and 31.6% with tirzepatide. All three reduced fat and lean mass and lowered energy expenditure [10].
- Combination with an amylin analogue. In diet-induced obese rats, retatrutide plus cagrilintide reduced food intake and body weight more than either drug alone or matched combinations built on semaglutide or tirzepatide. Pair-feeding experiments showed the extra weight loss could not be explained by reduced food intake alone [11].
- Alcohol cues. In a drug-discrimination study in male and female rats, acute retatrutide, like semaglutide and tirzepatide, attenuated the interoceptive effects of alcohol [12]. This is a behavioural signal in rats, not evidence about drinking in people.
Where phase 3 stands
The phase 3 TRIUMPH-1 trial randomised 2339 adults with obesity without diabetes for 80 weeks; mean weight change was -25.0% with the 12 mg regimen versus -3.9% with placebo [13]. Its abstract does not report appetite or eating-behaviour outcomes. A phase 2 body composition substudy in type 2 diabetes found that the proportion of lean mass lost relative to weight lost was similar to other obesity treatments [14].
What remains open
- Exploratory status. The appetite analyses were exploratory or post hoc, and all trials were sponsor-funded [5,3].
- Intake versus expenditure. How much of the weight loss comes from eating less versus the glucagon-driven rise in energy expenditure has not been measured directly in people [1,11].
- Validated tools. The EBAQ and WES still need psychometric validation before they can serve as trial endpoints [8,9].
- Durability. Whether reported changes in hunger and eating persist over the 80-week phase 3 horizon, or after treatment stops, has not yet been reported.
Retatrutide 10mg at PurixLab
Retatrutide 10mg: a labelled lyophilized research vial with 10mg per vial, C$119 per vial (CAD, before tax), supplied for laboratory research only. Batch documentation is available on request. Product page: purixlab.com/product/retatrutide-10mg/.
PurixLab ships within Canada only, from stock held in Toronto. Standard shipping is C$15, and shipping is free when the product subtotal is C$200 or more after discounts. Orders outside the GTA ship by Canada Post Xpresspost. Prices are in CAD and taxes are calculated from your shipping address at checkout.
In Toronto and the GTA, our own team delivers orders the same day or the next day. There is no fixed GTA delivery fee: after you place your order, we email you to confirm the delivery time and any delivery charge, and then you pay. There is no storefront or local pickup.
Payment is by Interac e-Transfer (instructions are shown at checkout) or by cryptocurrency through Plisio (Bitcoin, Ethereum, USDT and more): choose Plisio at checkout and you are sent to a secure Plisio payment page after placing the order. Current offers and any pack pricing are shown on the product page and in your cart; offers do not stack.
For laboratory research use only. Not for human or veterinary use, not for consumption, injection or application to skin, and purchasers must be 18 or older. The studies summarised above describe specific materials in published research; they are not claims about any PurixLab product.
Questions or batch documentation requests: [email protected] · Shipping & Delivery · Toronto & GTA delivery · PurixLab FAQ
References
- Coskun T, Urva S, Roell WC, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PubMed 35985340 · doi:10.1016/j.cmet.2022.07.013
- Urva S, O'Farrell L, Du Y, et al. The novel GIP, GLP-1 and glucagon receptor agonist retatrutide delays gastric emptying. Diabetes Obes Metab. 2023;25(9):2784-2788. PubMed 37311727 · doi:10.1111/dom.15167
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity – A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PubMed 37366315 · doi:10.1056/NEJMoa2301972
- Rosenstock J, Frias J, Jastreboff AM, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PubMed 37385280 · doi:10.1016/S0140-6736(23)01053-X
- Kanu C, Boye KS, Poon JL, et al. Appetite, eating attitudes, and eating behaviours during treatment with retatrutide in adults with type 2 diabetes: Results of a phase 2 study. Diabetes Obes Metab. 2025;27(12):6988-6998. PubMed 40916752 · PMC12587234 · doi:10.1111/dom.70097
- Kanu C, Wu Q, Poon JL, et al. Association between patient-reported eating behaviours and weight change: Secondary analyses of a randomized, double-blind trial comparing retatrutide and placebo in people with obesity or overweight. Diabetes Obes Metab. 2025;27(10):6088-6091. PubMed 40735804 · PMC12409224 · doi:10.1111/dom.16662
- Goetz IA, Kanu C, Hoover A, et al. Perceived benefits of treatment for obesity with retatrutide: A qualitative study of patients in a phase 2 clinical trial. Obes Pillars. 2025;16:100220. PubMed 41216380 · PMC12596213 · doi:10.1016/j.obpill.2025.100220
- Kanu C, Clucas C, Skalicky A, et al. Development and Content Evaluation of the Eating Behavior and Appetite Questionnaire (EBAQ) for Individuals with Obesity. Adv Ther. 2026;43(1):150-164. PubMed 41201783 · PMC12858465 · doi:10.1007/s12325-025-03386-2
- Kanu C, Kimel M, Goetz I, et al. Development of the Weight and Emotions Scale (WES). Obes Sci Pract. 2026;12(1):e70119. PubMed 41589220 · PMC12832084 · doi:10.1002/osp4.70119
- Hitaka K, Sugawara T, Matsumoto M, et al. Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide on MC4R deficient obesity and their comparison. Int J Obes (Lond). 2026;50(4):928-937. PubMed 41723268 · PMC13056526 · doi:10.1038/s41366-026-02025-2
- Petersen J, Merrild C, Holm SK, et al. Cagrilintide and retatrutide combination therapy enhances weight loss and metabolic outcomes in obese male rats. Nat Metab. 2026;8(10):2069-2083. PubMed 42744908 · doi:10.1038/s42255-026-01603-y
- Windram M, Lovelock DF, Carew JM, et al. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology (Berl). 2026;243(5):1185-1197. PubMed 40699363 · PMC13242451 · doi:10.1007/s00213-025-06854-3
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. 2026. PubMed 42814954 · doi:10.1056/NEJMoa2604169
- Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025;13(8):674-684. PubMed 40609566 · doi:10.1016/S2213-8587(25)00092-0